Category: Peptide Q&A
-
What peer-reviewed publications have demonstrated SLU-PP-332’s ability to reduce amyloid-beta plaque burden in transgenic Alzheimer’s models?
What peer-reviewed publications have demonstrated SLU-PP-332’s ability to reduce amyloid-beta plaque burden in transgenic Alzheimer’s models?
-
What neuroimaging data (e.g., fMRI, PET) in rodent models demonstrate SLU-PP-332’s impact on cerebral blood flow and metabolic activity in regions associated with memory and executive function?
What neuroimaging data (e.g., fMRI, PET) in rodent models demonstrate SLU-PP-332’s impact on cerebral blood flow and metabolic activity in regions assoc
-
Has SLU-PP-332 demonstrated protective effects against age-related hearing loss or retinal degeneration in animal models, and what pathways are involved?
Has SLU-PP-332 demonstrated protective effects against age-related hearing loss or retinal degeneration in animal models, and what pathways are involved
-
How does SLU-PP-332 compare to rapamycin in extending healthspan in C. elegans and mouse models, particularly in terms of mitochondrial function and proteostasis?
How does SLU-PP-332 compare to rapamycin in extending healthspan in C. elegans and mouse models, particularly in terms of mitochondrial function and pro
-
Does SLU-PP-332 cross the blood-brain barrier effectively, and what pharmacokinetic studies support its CNS bioavailability in non-human primates?
Does SLU-PP-332 cross the blood-brain barrier effectively, and what pharmacokinetic studies support its CNS bioavailability in non-human primates?
-
What impact does SLU-PP-332 have on neuroinflammation, particularly microglial activation and IL-1β/ TNF-α release, in the context of chronic neurodegeneration?
What impact does SLU-PP-332 have on neuroinflammation, particularly microglial activation and IL-1β/ TNF-α release, in the context of chronic neurodegen
-
What are the challenges in scaling up the synthesis of SLU-PP-332 for clinical use, and how might this affect cost and accessibility?
What are the challenges in scaling up the synthesis of SLU-PP-332 for clinical use, and how might this affect cost and accessibility?
-
What is the precise molecular mechanism by which SLU-PP-332 modulates mitochondrial function in neuronal cells, and how does it differ from other known mitochondrial enhancers like MitoQ or SS-31?
What is the precise molecular mechanism by which SLU-PP-332 modulates mitochondrial function in neuronal cells, and how does it differ from other known
-
How does SLU-PP-332 interact with the electron transport chain complex I, and what evidence supports its role in reducing reactive oxygen species (ROS) production at the mitochondrial level?
How does SLU-PP-332 interact with the electron transport chain complex I, and what evidence supports its role in reducing reactive oxygen species (ROS)
-
In preclinical models of traumatic brain injury, what specific neurorestorative effects has SLU-PP-332 demonstrated, and how do these compare to those of standard neuroprotective agents like nimodipine?
In preclinical models of traumatic brain injury, what specific neurorestorative effects has SLU-PP-332 demonstrated, and how do these compare to those o